5-Methoxy 2-aminoindane - Clearmind Medicine
Alternative Names: 5-MeO-AI - Clearmind Medicine; CMND-100; MEAI - Clearmind MedicineLatest Information Update: 20 May 2025
At a glance
- Originator Clearmind Medicine
- Developer Clearmind Medicine; SciSparc
- Class Amines; Antipsychotics; Drug withdrawal therapies; Ethers; Indans; Obesity therapies
- Mechanism of Action 5-HT1A serotonin receptor modulators; Serotonin 5-HT2A receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Alcoholism
- Preclinical Cocaine-related disorders; Metabolic syndrome; Obesity
Most Recent Events
- 12 May 2025 SciSparc and Clearmind Medicine has patent pending for a psychedelic-based combination therapy for the treatment of cocaine addiction in Europe
- 12 May 2025 Pharmacodynamics data from a preclinical trial in Cocaine related disorders released by Clearmind Medicine
- 17 Apr 2025 The United States Patent Office issues a Notice of Allowance for 5-Methoxy 2-aminoindane in USA